Literature DB >> 12077582

Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis.

Osvaldo Correia1, Luís Delgado, Isabel Leal Barbosa, Fernando Campilho, José Fleming-Torrinha.   

Abstract

BACKGROUND: Toxic epidermal necrolysis is a severe, usually drug-induced disease that shares clinical, histologic, and immunologic similarities with the severe forms of cutaneous acute graft-versus-host disease.
OBJECTIVE: Our purpose was to further characterize common immune-inflammatory pathways in these skin disorders by measurement of different cytokines.
METHODS: Evaluation of serum levels of interleukin 10 (IL-10), tumor necrosis factor alpha, IL-6, and soluble IL-6 receptor in the early phase of both diseases and in blister fluid of toxic epidermal necrolysis.
RESULTS: Serum levels of IL-10 and IL-6 were significantly higher in patients with toxic epidermal necrolysis (P =.0001) and acute graft-versus-host disease (P =.001) compared with those of blood donors. We found an increase in IL-6 levels in blister fluid and significantly higher levels of IL-10 (P =.018) and tumor necrosis factor alpha (P =.028) in blister fluid compared with serum in patients with toxic epidermal necrolysis.
CONCLUSION: A similar serum cytokine profile of toxic epidermal necrolysis and acute graft-versus-host disease further emphasizes common immunologic mechanisms. The presence of inflammatory cytokines, IL-6 and tumor necrosis factor alpha, in the blister fluid of patients with toxic epidermal necrolysis is associated with significantly higher levels of IL-10, which through its down-regulatory role, may be involved in limitation of the disease extension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12077582     DOI: 10.1067/mjd.2002.120473

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  12 in total

1.  Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.

Authors:  Lois La Grenade; Lauren Lee; Joyce Weaver; Renan Bonnel; Claudia Karwoski; Laura Governale; Allen Brinker
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions.

Authors:  Shoko Mori; Alanna Hickey; Stephen W Dusza; Mario E Lacouture; Alina Markova
Journal:  J Am Acad Dermatol       Date:  2018-10-26       Impact factor: 11.527

3.  New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.

Authors:  Philippe Paquet; Gérald E Piérard
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

Review 4.  Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances.

Authors:  Teresa Bellón
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.228

Review 5.  Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions.

Authors:  Shih-Chi Su; Wen-Hung Chung
Journal:  Toxins (Basel)       Date:  2014-01-03       Impact factor: 4.546

Review 6.  An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity.

Authors:  Chun-Bing Chen; Riichiro Abe; Ren-You Pan; Chuang-Wei Wang; Shuen-Iu Hung; Yi-Giien Tsai; Wen-Hung Chung
Journal:  J Immunol Res       Date:  2018-02-13       Impact factor: 4.818

7.  Intensive Care in a Patient with Toxic Epidermal Necrolysis.

Authors:  J Wallenborn; M Fischer
Journal:  Case Rep Crit Care       Date:  2017-11-01

8.  Desmoglein1 Deficiency Is a Potential Cause of Cutaneous Eruptions Induced by Shuanghuanglian Injection.

Authors:  Yidan Zhang; Xiujun Zhang; Shanshan Fan; Lili Song; Zhen Yang; Pengwei Zhuang; Yanjun Zhang
Journal:  Molecules       Date:  2018-06-19       Impact factor: 4.411

Review 9.  An Updated Review of the Diagnostic Methods in Delayed Drug Hypersensitivity.

Authors:  Ana Copaescu; Andrew Gibson; Yueran Li; Jason A Trubiano; Elizabeth J Phillips
Journal:  Front Pharmacol       Date:  2021-01-12       Impact factor: 5.810

10.  Association of interleukin-6 and tumor necrosis factor-α with mortality in hospitalized patients with cancer.

Authors:  Joseph R Stoll; Toral S Vaidya; Shoko Mori; Stephen W Dusza; Mario E Lacouture; Alina Markova
Journal:  J Am Acad Dermatol       Date:  2020-03-12       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.